The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Cellular and Molecular Mechanisms of Metformin Action
Open accessAbstract
Metformin is a first-line therapy for the treatment of type 2 diabetes, due to its robust glucose-lowering effects, well-established safety profile, and relatively low cost. While metformin has been shown to have pleotropic effects on glucose metabolism, there is a general consensus that the major glucose-lowering effect in patients with type 2 diabetes is mostly mediated through inhibition of hepatic gluconeogenesis. However, despite decades of research, the mechanism by which metformin inhibits this process is still highly debated. A key reason for these discrepant effects is likely due to the inconsistency in dosage of metformin across studies. Widely studied mechanisms of action, such as complex I inhibition leading to AMPK activation, have only been observed in the context of supra-pharmacological (>1 mM) metformin concentrations, which do not occur in the clinical setting. Thus, these mechanisms have been challenged in recent years and new mechanisms have been proposed. Based on the observation that metformin alters cellular redox balance, a redox-dependent mechanism of action has been described by several groups. Recent studies have shown that clinically relevant (50-100 μM) concentrations of metformin inhibit hepatic gluconeogenesis in a substrate-selective manner both in vitro and in vivo, supporting a redox-dependent mechanism of metformin action. Here, we review the current literature regarding metformin's cellular and molecular mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 1. Regulation of hepatic gluconeogenesis. Hepatic gluconeogenesis is regulated through allostery, substrate availability, redox balance, and gene expression. WAT lipolysis produces glycerol and NEFA, which can both independently stimulate hepatic gluconeogenesis. NEFA enters mitochondrial β-oxidation which produces acetyl-CoA, an allosteric activator of PC. PC catalyzes the conversion of pyruvate to oxaloacetate, which can directly enter the gluconeogenic pathway. On the other hand, glycerol is itself a gluconeogenic substrate. Glycerol from WAT lipolysis is phosphorylated to G3P and converted to DHAP, a gluconeogenic intermediate, by GPD2. The reaction catalyzed by GPD2 is dependent on cellular redox state and is inhibited by a high [NADH]:[NAD+] ratio. Similarly, gluconeogenesis from lactate is redox-regulated, because the conversion of lactate to pyruvate by LDH is inhibited by a high [NADH]:[NAD+] ratio. Transcriptional regulation of PCK1 and G6PC is coordinated by the opposing actions of glucagon and insulin. When insulin binds its receptor, AKT is activated and promotes nuclear exclusion of FOXO1, which decreases gluconeogenic gene expression. In contrast, glucagon binds the glucagon receptor and promotes IP3R-I-mediated ER Ca++ release. This in turn activates CRTC2, which forms a complex with CREB and CBP, and promotes transcriptional upregulation of PCK1 and G6PC. Abbreviations: CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; DKI, double knock-in; FOXO, Forkhead box O; G3P, glycerol-3-phosphate; GCGR, glucagon receptor; INSR, insulin receptor; LDH, lactate dehydrogenase; NEFA, nonesterified fatty acid; PC, pyruvate carboxylase; WAT, white adipose tissue;](https://figures.cochat.ai/paper-figures/1650a051106e489eaed9e668fde14524/cellular-and-molecular-mechanisms-of-metformin-action-figure-1.jpg)
![Figure 2. Proposed mechanisms of metformin action. Complex I inhibition (top panel). Inhibition of complex I is central to several proposed mechanisms of metformin action. Following complex I inhibition, AMPK is activated by increased AMP levels, leading to inhibition of CRTC2 and preventing formation of the CREB-CBP-CRTC2 complex (orange boxes). AMPK also phosphorylates and inhibits ACC1 and 2, which promotes fat oxidation and decreases lipogenesis (purple boxes). Additionally, increased AMP is proposed to inhibit hepatic gluconeogenesis independently of AMPK. High AMP prevents glucagon-stimulated production of cAMP and therefore antagonizes hepatic glucagon action (pink boxes). AMP also allosterically inhibits FBP1, which directly inhibits the gluconeogenic pathway (blue boxes). Increased cytosolic redox (bottom panel). Metformin inhibition of GPD2 reduces the conversion of G3P to DHAP which impairs gluconeogenesis from glycerol and simultaneously increases the cytosolic [NADH]:[NAD+] ratio. LDH is inhibited by the increased [NADH]:[NAD+] ratio, thus reducing gluconeogenesis from lactate. Metformin inhibition of GPD2 is the only proposed mechanism that is independent of Complex I inhibition and produces substrate-selective inhibition of gluconeogenesis. Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, adenosine monophosphate–activated protein kinase; CBP, CREB-binding protein; CREB, cAMP-responsive element-binding protein 1; CRTC2, CREB-regulated transcription co-activator 2; DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphatase; FDP, fructose 1,6-diphosphate; G3P, glycerol-3-phosphate; GLP-1, glucagon-like peptide-1; GPD, glycerol-3-phosphate dehydrogenase; LDH, lactate dehydrogenase; OCT1, organic cation transporter 1.](https://figures.cochat.ai/paper-figures/2b1f1dba40444156a0a1c347b1b77f0b/cellular-and-molecular-mechanisms-of-metformin-action-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Metformin primarily reduces hepatic glucose production, while GLP-1RAs enhance insulin secretion in response to meals20–22.”
From Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials (2025) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294
Self-citationOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Self-citationForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Self-citationMetformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096 · cited 1×
“The cancer field has begun to explore the antitumor effect of metformin as a potential treatment for certain cancers (23, 24), and the first trials of metformin for treating aging in healthy humans are currently underway (25, 26).”
BackgroundMetformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Self-citationMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationMusi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Self-citationMagnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757
Self-citationMetformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Perry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719
Self-citationHawley, S. A., Gadalla, A. E., Olsen, G. S., & Hardie, D. G. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2420 · Cited by 696
The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes
King, P., Peacock, I., & Donnelly, R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00092.x · Cited by 695
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Bharath, L. P., Agrawal, M., McCambridge, G., Nicholas, D. A., Hasturk, H., Liu, J., Jiang, K., Liu, R., Guo, Z., Deeney, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.015 · Cited by 614 · cited 1×
“Several mechanisms have been proposed linking metformin action and increased life-and health-span; most recently, metformin was shown to alleviate age-associated inflammation by increasing autophagy and improving mitochondrial function (27).”
BackgroundMcGarry, J. D., Leatherman, G. F., & Foster, D. W. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34693-8 · Cited by 600
Carling, D., Zammit, V. A., & Hardie, D. G. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80292-2 · Cited by 599
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Quantitation of Hepatic Glycogenolysis And Gluconeogenesis in Fasting Humans With 13 C NMR
Rothman, D. L., Magnusson, I., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1991) · Science · doi:10.1126/science.1948033 · Cited by 546
Self-citationHe, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., & Wondisford, F. E. (2009) · Cell · doi:10.1016/j.cell.2009.03.016 · Cited by 481
Cusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Structure, mechanism and regulation of pyruvate carboxylase
Jitrapakdee, S., St Maurice, M., Rayment, I., Cleland, W. W., Wallace, J. C., & Attwood, P. V. (2008) · Biochemical Journal · doi:10.1042/bj20080709 · Cited by 451
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448 · cited 2×
“…concentrations following oral metformin dosing are plasma concentrations of metformin in the portal vein (~50-60 µ M) following oral metformin dosing (50 mg/kg), which similar to other orally ingested substances range 2-to 3-fold higher than systemic metformin concentrations (~10-40 µ M) (54, 55).”
BackgroundMethodSavage, D. B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27300 · Cited by 447
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441
Szabo, C., Ransy, C., Módis, K., Andriamihaja, M., Murghes, B., Coletta, C., Olah, G., Yanagi, K., & Bouillaud, F. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12369 · Cited by 440
Hormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 426
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418
Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1
Lu, M., Wan, M., Leavens, K. F., Chu, Q., Monks, B. R., Fernandez, S., Ahima, R. S., Ueki, K., Kahn, C. R., & Birnbaum, M. J. (2012) · Nature Medicine · doi:10.1038/nm.2686 · Cited by 395
Justice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., Espeland, M. A., Marcovina, S., Pollak, M. N., Kritchevsky, S. B., et al. (2018) · GeroScience · doi:10.1007/s11357-018-0042-y · Cited by 359
Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30194-8 · Cited by 357
Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., Sabolić, I., Koepsell, H., & Brockmöller, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.92 · Cited by 349
Regulation of Hepatic Acetyl Coenzyme A Carboxylase by Phosphorylation and Dephosphorylation
Carlson, C. A., & Kim, K.-H. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44486-4 · Cited by 346
Keech, D. B., & Utter, M. F. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67874-3 · Cited by 324
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313
Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0146-4 · Cited by 307
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
Madiraju, A. K., Qiu, Y., Perry, R. J., Rahimi, Y., Zhang, X.-M., Zhang, D., Camporez, J.-P. G., Cline, G. W., Butrico, G. M., Kemp, B. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0125-4 · Cited by 297
Self-citationRebrin, K., Steil, G. M., Mittelman, S. D., & Bergman, R. N. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118846 · Cited by 289
Ekberg, K., Landau, B. R., Wajngot, A., Chandramouli, V, Efendic, S., Brunengraber, H., & Wahren, J. (1999) · Diabetes · doi:10.2337/diabetes.48.2.292 · Cited by 287
Dujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2015) · Diabetes · doi:10.2337/db14-1388 · Cited by 278
Burgess, S. C., He, T., Yan, Z., Lindner, J., Sherry, A. D., Malloy, C. R., Browning, J. D., & Magnuson, M. A. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.004 · Cited by 276
Bailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275
Goedeke, L., Bates, J., Vatner, D. F., Perry, R. J., Wang, T., Ramirez, R., Li, L., Ellis, M. W., Zhang, D., Wong, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.30097 · Cited by 259
Self-citationJuhan-Vague, I., Vague, P., Alessi, M., Badier, C., Valadier, J., Aillaud, M.-F., & Atlan, C. (1987) · PubMed · Cited by 218
FRAZE, E., DONNER, C. C., SWISLOCKI, A. L. M., CHIOU, Y. A. M., CHEN, Y. D. I., & REAVEN, G. M. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-5-807 · Cited by 215
Mechanism of metformin action in non-insulin-dependent diabetes
Jackson, R. A., Hawa, M. I., Jaspan, J. B., Sim, B. M., DiSilvio, L., Featherbe, D., & Kurtz, A. B. (1987) · Diabetes · doi:10.2337/diab.36.5.632 · Cited by 202
AMPK functions as an adenylate charge-regulated protein kinase
Oakhill, J. S., Scott, J. W., & Kemp, B. E. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.12.006 · Cited by 200
High and typical 18F-FDG bowel uptake in patients treated with metformin
Gontier, E., Fourme, E., Wartski, M., Blondet, C., Bonardel, G., Le Stanc, E., Mantzarides, M., Foehrenbach, H., Pecking, A.-P., & Alberini, J.-L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0563-6 · Cited by 196
Nurjhan, N., Consoli, A., & Gerich, J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115558 · Cited by 195
ACCELERATION OF RENAL GLUCONEOGENESIS BY KETONE BODIES AND FATTY ACIDS
KREBS, H., SPEAKE, R., & HEMS, R. (1965) · Biochemical Journal · doi:10.1042/bj0940712 · Cited by 194
Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis
Perry, R. J., Zhang, X.-M., Zhang, D., Kumashiro, N., Camporez, J.-P. G., Cline, G. W., Rothman, D. L., & Shulman, G. I. (2014) · Nature Medicine · doi:10.1038/nm.3579 · Cited by 193
Self-citationMacDonald, M. J. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68840-x · Cited by 190
Migoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N. K., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.184 · Cited by 179
CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & REAVEN, G. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-17 · Cited by 177
Samuel, V. T., Beddow, S. A., Iwasaki, T., Zhang, X.-M., Chu, X., Still, C. D., Gerhard, G. S., & Shulman, G. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812547106 · Cited by 176
Self-citationAre Metformin Doses Used in Murine Cancer Models Clinically Relevant
Chandel, N. S., Avizonis, D., Reczek, C. R., Weinberg, S. E., Menz, S., Neuhaus, R., Christian, S., Haegebarth, A., Algire, C., & Pollak, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.010 · Cited by 176 · cited 1×
“…metformin in rodents with ad libitum access to metformin-treated drinking water results in inconsistent plasma metformin concentrations, possibly due to variability in drinking and/or absorption from the gut, with studies reporting plasma concentrations ranging from 5 µ M to 180 µ M (48, 52, 53).”
BackgroundLeptin Mediates a Glucose-Fatty Acid Cycle to Maintain Glucose Homeostasis in Starvation
Perry, R. J., Wang, Y., Cline, G. W., Rabin-Court, A., Song, J. D., Dufour, S., Zhang, X. M., Petersen, K. F., & Shulman, G. I. (2018) · Cell · doi:10.1016/j.cell.2017.12.001 · Cited by 173
Self-citationMetformin: a review of its pharmacological properties and therapeutic use.
Ls, H. (1979) · PubMed · Cited by 173
Pharmacological Studies of a New Oral Hypoglycemic Drug
Ungar, G., Freedman, L., & Shapiro, S. L. (1957) · Experimental Biology and Medicine · doi:10.3181/00379727-95-23163 · Cited by 172
Thakur, S., Daley, B., Gaskins, K., Vasko, V. V., Boufraqech, M., Patel, D., Sourbier, C., Reece, J. M., Cheng, S.-Y., Kebebew, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3167 · Cited by 169
Cao, J., Meng, S., Chang, E., Beckwith-Fickas, K., Xiong, L., Cole, R. N., Radovick, S., Wondisford, F. E., & He, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567271 · Cited by 169
STUDIES IN THE METABOLISM CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES
Watanabe, C. K. (1918) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86579-6 · Cited by 163
Therapeutic Concentrations of Metformin: A Systematic Review
Kajbaf, F., Broe, M. E. D., & Lalau, J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0323-x · Cited by 160
Esquejo, R. M., Salatto, C. T., Delmore, J. E., Albuquerque, B., Reyes, A. R., Shi, Y., Moccia, R., Cokorinos, E., Peloquin, M., Monetti, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.009 · Cited by 158
Metformin selectively targets redox control of complex I energy transduction
Cameron, A., Logie, L., Patel, K., Erhardt, S., Bacon, S., Middleton, P. K., Harthill, J. E., Forteath, C., Coats, J. T., Kerr, C., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.08.018 · Cited by 157
Johnson, A. B., Webster, J. M., Sum, C. F., Heseltine, L., Argyraki, M., Cooper, B. G., & Taylor, R. (1993) · Metabolism · doi:10.1016/0026-0495(93)90284-u · Cited by 154
Interrelationships between malate-aspartate shuttle and citric acid cycle in rat heart mitochondria
LaNoue, K. F., & Williamson, J. R. (1971) · Metabolism · doi:10.1016/0026-0495(71)90087-4 · Cited by 152
Werner, E. A., & Bell, J. (1922) · Journal of the Chemical Society Transactions · doi:10.1039/ct9222101790 · Cited by 151
Peripheral effects of insulin dominate suppression of fasting hepatic glucose production
Ader, M., & Bergman, R. N. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.6.e1020 · Cited by 149
Gormsen, L. C., Sundelin, E. I. O., Jensen, J., Vendelbo, M. H., Jakobsen, S., Munk, O. L., Christensen, M. M. H., Brøsen, K., Frøkiær, J., & Jessen, N. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177774 · Cited by 147
Importance of the intestine as a site of metformin‐stimulated glucose utilization
Bailey, C. J., Mynett, K. J., & Page, T. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb13128.x · Cited by 147
Shields, W., Thompson, K., Grice, G. A., Harrison, S. A., & Coyle, W. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09105462 · Cited by 141
Johanns, M., Lai, Y.-C., Hsu, M., Jacobs, R., Vertommen, D., van Sande, J., Dumont, J., Woods, A., Carling, D., Hue, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms10856 · Cited by 138
Sindelar, D. K., Balcom, J. H., Chu, C. A., Neal, D. W., & Cherrington, A. D. (1996) · Diabetes · doi:10.2337/diab.45.11.1594 · Cited by 134 · cited 1×
“Two studies showed that portal infusions of insulin in dogs reduced HGP; however, suppression of HGP tracked very closely with peripheral insulin levels rather than portal insulin (112, 113).”
BackgroundMetformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice
Zu, T., Guo, S., Bardhi, O., Ryskamp, D. A., Li, J., Khoramian Tusi, S., Engelbrecht, A., Klippel, K., Chakrabarty, P., Nguyen, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005748117 · Cited by 133
Galuska, D., Nolte, L. A., Zierath, J. R., & Wallberg‐Henriksson, H. (1994) · Diabetologia · doi:10.1007/bf00404340 · Cited by 126
Florez, H. J., Luo, J., Castillo-Florez, S., Mitsi, G., Hanna, J., Tamariz, L. J., Palacio, A., Nagendran, S., & Hagan, M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2128 · Cited by 126
Frid, A., Sterner, G. N., Löndahl, M., Wiklander, C., Cato, A., Vinge, E., & Andersson, A. (2010) · Diabetes Care · doi:10.2337/dc09-1284 · Cited by 126
Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation
Timmins, P., Donahue, S., Meeker, J. B., & Marathe, P. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00004 · Cited by 120
Cellular Responses to the Metal-Binding Properties of Metformin
Logie, L., Harthill, J. E., Patel, K., Bacon, S., Hamilton, D. L., Macrae, K., McDougall, G. J., Wang, H., Xue, L., Jiang, H., et al. (2012) · Diabetes · doi:10.2337/db11-0961 · Cited by 116
Effect of metformin on glucose metabolism in mouse soleus muscle.
Bailey, C. J., & Puah, J. A. (1986) · PubMed · Cited by 112
Effects of Metformin on Lactate Uptake and Gluconeogenesis in the Perfused Rat Liver
Radziuk, J., Zhang, Z. M., Wiernsperger, N. F., & Pye, S. (1997) · Diabetes · doi:10.2337/diab.46.9.1406 · Cited by 111
Widén, E., Eriksson, J. G., & Groop, L. (1992) · Diabetes · doi:10.2337/diab.41.3.354 · Cited by 110
The Effect of Alkylguanidines on Mitochondrial Metabolism
Chappell, J. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84013-9 · Cited by 110
Yu, J., Kruszynska, Y. T., Mulford, M. I., & Olefsky, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2414 · Cited by 110
Diarrhea and Metformin in a Diabetic Clinic
Dandona, P., Fonseca, V., Mier, A., & Beckett, A. G. (1983) · Diabetes Care · doi:10.2337/diacare.6.5.472 · Cited by 109
Nosadini, R., Avogaro, A., Trevisan, R., Valerio, A., Tessari, P., Duner, E., Tiengo, A., Velussi, M., Prato, S. D., de Kreutzenberg, S., et al. (1987) · Diabetes Care · doi:10.2337/diacare.10.1.62 · Cited by 109
Swislocki, A., Chen, Y. I., Golay, A., Chang, M. O., & Reaven, M. S. (1987) · Diabetologia · doi:10.1007/bf00277318 · Cited by 103
Biguanides. A review of history, pharmacodynamics and therapy.
Schäfer, G. (1983) · PubMed · Cited by 101
Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes
Pagano, G., Tagliaferro, V., Carta, Q., Caselle, M. T., Bozzo, C., Vitelli, F., Trovati, M., & Cocuzza, E. (1983) · Diabetologia · doi:10.1007/bf00251823 · Cited by 94
Karlsson, H., Hällsten, K., Björnholm, M., Tsuchida, H., Chibalin, A., Virtanen, K. A., Heinonen, O. J., Lönnqvist, F., Nuutila, P., & Zierath, J. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1459 · Cited by 92
Alshawi, A., & Agius, L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006670 · Cited by 88
Puhakainen, I., Koivisto, V. A., & Yki‐Järvinen, H. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517368 · Cited by 86
Xie, J., Ye, J., Cai, Z., Luo, Y., Zhu, X., Deng, Y., Feng, Y., Liang, Y., Liu, R., Han, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2852 · Cited by 83
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients
Gin, H., Messerchmitt, C., Brottier, E., & Aubertin, J. (1985) · Metabolism · doi:10.1016/0026-0495(85)90139-8 · Cited by 82
Giacca, A., Fisher, S. J., Shi, Z. Q., Gupta, R., Lickley, H. L. A., & Vranić, M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116051 · Cited by 80
Characterization of shuttle mechanisms for the transport of reducing equivalents into mitochondria
Cederbaum, A. I., Lieber, C. S., Beattie, D. S., & Rubin, E. (1973) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(73)90571-7 · Cited by 78
Sequence and tissue-dependent RNA expression of mouse FAD-linked glycerol-3-phosphate dehydrogenase
Koza, R. A., Kozak, U. C., Brown, L. J., Leiter, E. H., Macdonald, M. J., & Kozak, L. P. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0536 · Cited by 76
Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice
Buettner, C., Patel, R. D., Muse, E. D., Bhanot, S., Monia, B. P., McKay, R., Obici, S., & Rossetti, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23109 · Cited by 72
Sistare, F. D., & Haynes, R. C. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38940-8 · Cited by 71
Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes
Konopka, A. R., Esponda, R. R., Robinson, M. M., Johnson, M. L., Carter, R. E., Schiavon, M., Cobelli, C., Wondisford, F. E., Lanza, I. R., & Nair, K. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.024 · Cited by 71
The Relation of Insulin to Liver Metabolism
Levine, R., & Fritz, I. B. (1956) · Diabetes · doi:10.2337/diab.5.3.209 · Cited by 70
Wu, T., Thazhath, S. S., Bound, M. J., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.004 · Cited by 70
Deficiency of Mitochondrial Glycerol 3‐Phosphate Dehydrogenase Contributes to Hepatic Steatosis
Zheng, Y., Qu, H., Xiong, X., Wang, Y., Liu, X., Zhang, L., Liao, X., Liao, Q., Sun, Z., Ouyang, Q., et al. (2019) · Hepatology · doi:10.1002/hep.30507 · Cited by 67
Metformin Alters Locomotor and Cognitive Function and Brain Metabolism in Normoglycemic Mice
Li, W., Chaudhari, K., Shetty, R. A., Winters, A., Gao, X., Hu, Z., Ge, W., Sumien, N., Forster, M. J., Liu, R., et al. (2019) · Aging and Disease · doi:10.14336/ad.2019.0120 · Cited by 66
Harding, J. W., Pyeritz, E. A., Copeland, E. S., & White, H. B. (1975) · Biochemical Journal · doi:10.1042/bj1460223 · Cited by 65
Drahota, Z., Páleníčková, E., Endlicher, R., Milerová, M., Brejchová, J., Vošahlíková, M., Svoboda, P., Kazdova, L., Kalous, M., Červinková, Z., et al. (2014) · Physiological Research · doi:10.33549/physiolres.932600 · Cited by 64
Gormsen, L. C., Søndergaard, E., Christensen, N. L., Brøsen, K., Jessen, N., & Nielsen, S. (2019) · Diabetologia · doi:10.1007/s00125-019-4872-7 · Cited by 64
Effects of visceral adiposity on glycerol pathways in gluconeogenesis
Neeland, I. J., Hughes, C., Ayers, C. R., Malloy, C. R., & Jin, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.11.008 · Cited by 63
Wang, Y., Nasiri, A. R., Damsky, W., Perry, C. J., Zhang, X., Rabin-Court, A., Pollak, M., Shulman, G. I., & Perry, R. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.008 · Cited by 57
Self-citationGONG, D.-W., Bi, S., Weintraub, B. D., & Reitman, M. L. (1998) · DNA and Cell Biology · doi:10.1089/dna.1998.17.301 · Cited by 56
Magno, L. D., Manni, S., Pastena, F. D., Coni, S., Macone, A., Cairoli, S., Sambucci, M., Infante, P., Moretti, M., Petroni, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.024 · Cited by 56
Biomolecular Mode of Action of Metformin in Relation to Its Copper Binding Properties
Repiščák, P., Erhardt, S., Rena, G., & Paterson, M. J. (2014) · Biochemistry · doi:10.1021/bi401444n · Cited by 55
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria
Guo, Z., Sevrioukova, I. F., Denisov, I. G., Zhang, X., Chiu, T.-L., Thomas, D. G., Hanse, E. A., Cuellar, R. A. D., Grinkova, Y. V., Langenfeld, V. W., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.009 · Cited by 54
A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo
Previs, S. F., Cline, G. W., & Shulman, G. I. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e154 · Cited by 52
Self-citationKiersztan, A., Modzelewska, A., Jarzyna, R., Jagielska, E., & Bryła, J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00861-4 · Cited by 50
Lewis, A., Miller, J. J. J. J., McCallum, C., Rider, O. J., Neubauer, S., Heather, L. C., & Tyler, D. J. (2016) · Diabetes · doi:10.2337/db16-0804 · Cited by 50
Effects of guanidine derivatives on mitochondrial function
Davidoff, F. F. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105918 · Cited by 50
Rains, S. G. H., Wilson, G. A., Richmond, W., & Elkeles, R. S. (1989) · Journal of the Royal Society of Medicine · doi:10.1177/014107688908200213 · Cited by 47
Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., Gooding, K. M., Gates, P. E., Looker, H. C., Dove, F., Gonçalves, I., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13519 · Cited by 45
Pedersen, O., Nielsen, O. H., Bak, J. F., Richelsen, B., Beck‐Nielsen, H., & Sørensen, N. S. (1989) · Diabetic Medicine · doi:10.1111/j.1464-5491.1989.tb01156.x · Cited by 42
Sugano, T., Shiota, M., Tanaka, T., MIYAMAE, Y., SHIMADA, M., & Oshino, N. (1980) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a132721 · Cited by 42
GUANIDINE STRUCTURE AND HYPOGLYCEMIA
Bischoff, F., Sahyun, M. R. V., & Long, M. L. (1929) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83816-9 · Cited by 40
Regulation of hepatic gluconeogenesis in the guinea pig by fatty acids and ammonia
Jomain-Baum, M., & Hanson, R. W. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40681-9 · Cited by 38
Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats
Qi, H., Nielsen, P. M., Schroeder, M., Bertelsen, L. B., Palm, F., & Laustsen, C. (2017) · Diabetologia · doi:10.1007/s00125-017-4445-6 · Cited by 35
MCCREIGHT, L. J., Mari, A., Coppin, L., Jackson, N., Umpleby, A. M., & Pearson, E. R. (2019) · Diabetologia · doi:10.1007/s00125-019-05042-1 · Cited by 34
Sato, T., Yoshida, Y., Morita, A., Mori, N., & Miura, S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.005 · Cited by 32
Iversen, A. B. B., Horsman, M. R., Jakobsen, S., Jensen, J., Garm, C., Jessen, N., Breining, P., Frøkiær, J., & Busk, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10010-z · Cited by 29
Cavallo‐Perin, P., Aluffi, E., Estivi, P., Bruno, A. M., Carta, Q., Pagano, G., & Lenti, G. (1989) · PubMed · Cited by 28
Gormsen, L. C., Søndergaard, E., Christensen, N. L., Jakobsen, S., Nielsen, E. N., Munk, O. L., Tolbod, L. P., Jessen, N., & Nielsen, S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13244 · Cited by 26
Jakobsen, S., Busk, M., Jensen, J., Munk, O. L., Zois, N. E., Alstrup, A. K. O., Jessen, N., & Frøkiær, J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169292 · Cited by 25
[Blood sugar-lowering effect of 1,1-dimethylbiguanide].
Sterne, J. A. C. (1958) · PubMed · Cited by 24
Calza, G., Nyberg, E., Mäkinen, M., Soliymani, R., Cascone, A., Lindholm, D., Barborini, E., Baumann, M., Lalowski, M. M., & Eriksson, O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00141 · Cited by 19
The effects of metformin on cardiovascular risk factors
Grant, P. J. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110507 · Cited by 18
Davidoff, F. F., Bertolini, D. R., & Haas, D. W. (1978) · Diabetes · doi:10.2337/diab.27.7.757 · Cited by 18
Metformin Affects Heme Function as a Possible Mechanism of Action
Li, X., Wang, X., & Snyder, M. P. (2018) · G3 Genes Genomes Genetics · doi:10.1534/g3.118.200803 · Cited by 18
Lietz, T., & Bryła, J. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1423 · Cited by 18
[Report on 5-years' experience with dimethylbiguanide (metformin, glucophage) in diabetic therapy].
Sterne, J. (1963) · PubMed · Cited by 17
Clinical experience with DBI (phenformin) in the management of diabetes.
McKENDRY, J. B., Kuwayti, K., & Rado, P. P. (1959) · PubMed · Cited by 16
OCT3 promoter haplotype is associated with metformin pharmacokinetics in Koreans
Kwon, E. Y., Chung, J., Park, H., Kim, B. M., Kim, M., & Choi, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-35322-6 · Cited by 16
Inhibitory Effect of Metformin on Oxidation of NADH-Dependent Substrates in Rat Liver Homogenate
Páleníčková, E., Cahová, M., Drahota, Z., Kazdová, L., & Kalous, M. (2011) · Physiological Research · doi:10.33549/physiolres.932193 · Cited by 14
Lietz, T., Winiarska, K., & Bryła, J. (1997) · Acta Biochimica Polonica · doi:10.18388/abp.1997_4428 · Cited by 13
Barber�, A., Gudayol, M., Eto, K., Corominola, H., Maechler, P., Mir�, O., Cardellach, F., & Gomis, R. (2003) · Diabetologia · doi:10.1007/s00125-003-1206-5 · Cited by 8
The mechanism of action of phenformin in starved rats
Evans, P. F., King, L. J., Parke, D. V., Margetts, G., & Jones, W. E. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90377-5 · Cited by 5
Hansen, S. H., & McCormack, J. G. (2002) · NMR in Biomedicine · doi:10.1002/nbm.773 · Cited by 5
Winiarska, K., Bozko, P. M., Lietz, T., et al. (1998) · Acta Biochimica Polonica · doi:10.18388/abp.1998_4278 · Cited by 4
GUANIDINE STRUCTURE AND HYPOGLYCEMIA. II
Bischoff, F., & Long, M. L. (1931) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09133-5 · Cited by 3
MacDonald, M. J., Ansari, I. H., Longacre, M. J., & Stoker, S. W. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.28.013334 · Cited by 2
Knaani, Z., & Klajman, A. (1959) · PubMed · Cited by 1
Research works printed but not linked: 2
- Hill, The Vegetable System.
- World Health Organization, 2011, WHO model list of essential medicines
Cited by
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response
Abu Shelbayeh, O., Arroum, T., Morris, S., & Busch, K. B. (2023) · Antioxidants · doi:10.3390/antiox12051075 · Cited by 552
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Metadata
- Authors
- LaMoia, T. E., & Shulman, G. I.
- Affiliations
- Yale University (US)
- Corresponding author
- Shulman, Gerald I
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-09-08
- Volume
- 42
- Issue
- 1
- Pages
- 77-96
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7846086
- OpenAlex
- W3084144806
- Cited by
- 791
- References
- 175
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 205 · 2023: 144 · 2022: 88 · 2021: 46 · 2020: 1
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (R01 DK114973, R01 DK113984, R01 DK116774, R01 DK119968, RC2 DK120534, P30 DK045735, GM007324)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, hepatic gluconeogenesis, glucose-lowering effect, AMPK activation, mitochondrial complex I inhibition, glucose metabolism
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Gluconeogenesis, Glucose, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.